Clinical Predictors of Response to Tocilizumab: A Retrospective Multicenter Study

Ercan S., Ergan B., ÖZUYGUR ERMİŞ S. S., Korkmaz P., Tasbakan M. S., Basoglu O. K., ...More

TURKISH THORACIC JOURNAL, vol.23, no.3, pp.225-230, 2022 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 3
  • Publication Date: 2022
  • Doi Number: 10.5152/turkthoracj.2022.21179
  • Journal Name: TURKISH THORACIC JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI)
  • Page Numbers: pp.225-230
  • Keywords: Tocilizumab, COVID-19, mortality, biomarkers, CALL score, COVID-19
  • Dokuz Eylül University Affiliated: Yes

Abstract

OBJECTIVE: A substantial number of patients with coronavirus disease-2019 (COVID-19) demonstrate severe infection. Cytokine storm is an underlying condition that worsens clinical outcomes. As an interleukin-6 receptor antagonist, tocilizumab is a promising treatment option for COVID-19. This study aimed to evaluate the clinical predictors of mortality for critically ill COVID-19 patients receiving tocilizumab therapy.